Neuromodulation strategies in postburn care for pain rehabilitation and scar remodelling Authors: Tianjiao Li, Qian Zhang, Xiaocan Hou, Fei Zhou, Julin Xie, Bin Shu, Shiyu Li, Junyou Zhu Published: 2026 ABSTRACT AbstractBurn injury causes acute physiological stress and leads to long-term complications, including persistent pain, impaired mobility and abnormal scar formation. These changes arise from alterations in neural signalling, inflammation and tissue remodelling and are not fully addressed by conventional treatments. Here, we review recent advances in neuromodulation strategies for postburn care and their potential to improve pain control, rehabilitation and scar outcomes. Neuromodulation approaches can suppress abnormal pain signalling and enhance endogenous inhibitory pathways. When integrated with rehabilitation, they support muscle function and promote adaptive brain–body interactions. Emerging evidence also suggests that early application of these interventions may improve wound healing and scar remodelling. Although clinical use remains limited, growing preclinical and early clinical data highlight the translational potential of neuromodulation to improve long-term recovery and quality of life after burn injury.Subject terms: Pain management, Neuroscience Introduction Burn injury remains a significant global health concern, affecting more than eleven million people who require medical care each year1–3. Despite continuous advances in emergency resuscitation and reconstructive surgery, survivors frequently experience long-term complications such as chronic pain, functional impairment and hypertrophic or dysregulated scar formation4. Postburn pain (PBP) is a multifactorial condition that persists throughout all stages of injury, progressing from acute nociceptive pain to chronic neuropathic pain that may last for years after wound closure5–7. Epidemiological studies indicate that more than half of severe burn survivors continue to experience persistent pain, often accompanied by hyperalgesia, dysesthesia and abnormal sensitivity to mechanical or thermal stimuli8. In addition, contractile scar tissue restricts joint mobility and produces continuous traction on adjacent normal skin, resulting in secondary pain and deformity9. These physical and psychological burdens markedly reduce quality of life, especially in children, where scar contracture may interfere with growth and development10–12. Current management relies primarily on multimodal analgesic regimens that combine opioids, nonsteroidal anti-inflammatory drugs, sedatives or anxiolytics with physical and psychological therapies13. However, these strategies often provide only transient symptom relief and do not adequately address the neuroinflammatory responses and maladaptive neuroplastic changes that sustain persistent pain14. Furthermore, when pharmacological treatment is insufficient and patients transition to invasive neuromodulation approaches such as Spinal Cord Stimulation, there is an inherent risk of complications. Contemporary real-world studies and systematic reviews indicate that lead migration or displacement occurs in approximately 10% to 14% of cases, while infection, the most common biological complication leading to device explantation, is typically reported in about 3% to 10% of patients15,16. Although severe neuraxial complications such as epidural haematoma are relatively rare, occurring in less than 0.5% of cases, the cumulative risk of mechanical failure and infection remains a significant barrier to long-term efficacy16. In addition, even after adequate wound healing, approximately 6% of patients still progress to chronic pain and disability17. This therapeutic gap, together with the procedural risks associated with current advanced interventions, highlights the urgent need for innovative strategies that can simultaneously achieve pain relief, functional recovery, and scar control while reducing procedural burden. Although severe neuraxial haematomas are less frequent (<0.5%), the cumulative risk of mechanical failure and infection remains a significant barrier to long-term success18. As a result, approximately 5–6% of patients progress to chronic pain and disability despite adequate wound healing19.This therapeutic gap, compounded by the procedural risks of current advanced interventions, highlights the urgent need for innovative approaches that integrate pain relief, functional recovery, and scar control within unified, potentially less invasive treatment strategies. Accumulating evidence indicates that chronic postburn pain, scar hypertrophy and motor dysfunction share overlapping neurobiological mechanisms20. Peripheral nerve injury, immune-inflammatory activation and dysregulated or excessive tissue remodelling interact to create a self-reinforcing pathological network. Damaged sensory fibres release neuropeptides such as substance P and calcitonin gene-related peptide, which amplify local inflammation and promote excessive fibroblast activation, leading to persistent nociceptive input and fibrosis21,22. Conversely, mechanical tension arising from hypertrophic scars compresses or stretches nerve endings, producing ectopic discharges and exacerbating pain23,24. This bidirectional interaction between the nervous system and the immune-fibrotic axis forms a vicious cycle that sustains pain and impedes rehabilitation25. Neuromodulation has therefore emerged as a promising strategy to interrupt this cycle by regulating abnormal neural activity and restoring homoeostatic communication among the neural, immune and musculoskeletal systems26,27. Techniques that range from noninvasive electrical or magnetic stimulation to implantable and bioelectronic interfaces have demonstrated the potential to reduce nociceptive transmission, enhance motor recovery and optimize scar remodelling28–33. This review summarizes current evidence on neuromodulation in postburn pain control, rehabilitation and scar management, with a focus on its translational relevance. It outlines how these approaches may help reduce pain, support functional recovery and improve quality of life in burn survivors. We also bring these aspects together within a neurobiological framework and discuss how neuromodulation may influence pain, motor dysfunction and fibrotic remodelling. This perspective provides a basis for developing multimodal and more individualized treatment strategies. Pathophysiological alterations following burn injury Burn injury represents a complex systemic pathological process that involves extensive destruction of skin structures, neural damage and sustained hypermetabolic stress. The resulting pathophysiological alterations extend beyond the local wound and manifest as coordinated dysfunction across multiple organ systems. These systemic responses include abnormal activity in both the central and peripheral nervous systems, degenerative changes in skeletal muscles and neuromuscular junctions, and dysregulated dermal collagen metabolism, leading to excessive fibrosis34. Severe pain originating from burn wounds arises through the combined effects of peripheral nociceptive activation and central sensitization, which together constitute the pathological substrate of acute and chronic pain35. Burn-induced hypermetabolic stress is accompanied by neuronal injury, increased protein catabolism and mitochondrial dysfunction, culminating in skeletal muscle atrophy and neuromuscular junction impairment, which contribute to persistent motor deficits36. Continuous neuroinflammation, immune-cell activation and abnormal neuropeptide release further promote fibroblast proliferation and excessive collagen deposition, ultimately resulting in hypertrophic or dysregulated scar formation accompanied by persistent pain or pruritus37. These alterations are highly interconnected. Neurogenic inflammation not only drives the transition from acute to chronic pain but also acts as a central mediator of scar hypertrophy38. Moreover, muscle atrophy and neuromuscular junction degeneration limit mobility and exacerbate scar contracture, which in turn exacerbates functional impairment39. A comprehensive understanding of these postburn pathophysiological changes and their interactions with pain, motor dysfunction and scar hypertrophy is essential for developing neuromodulation strategies that target multiple systems simultaneously to improve pain relief, rehabilitation outcomes and scar prevention. Mechanistic Insights into the Pathophysiology of Postburn Pain PBP is a multifactorial clinical syndrome driven by several overlapping mechanisms. Its pathophysiological basis primarily involves central sensitization, peripheral nerve injury and neurogenic inflammation (Fig. 1)14,40. This pain differs from other types of pain by its distinct temporal evolution, beginning with acute nociceptive pain that, under conditions such as persistent peripheral nerve injury, sustained neuroinflammation, or mechanical compression caused by scar contracture, can develop into chronic neuropathic pain. This biphasic nature not only intensifies the perception of pain but also profoundly impairs long-term quality of life. Understanding these dynamic maladaptive sensory processing is essential for refining clinical management and guiding the precise application of neuromodulation therapies41. Pathophysiological mechanisms involved in PBP. Thermal, electrical, or chemical burns induce peripheral nerve injury and abnormal nociceptive input, which activate glial cells and promote central sensitization within spinal and supraspinal pathways. Tissue injury simultaneously releases inflammatory mediators that stimulate nociceptors and initiate neurogenic inflammation mediated by CGRP, BDNF, and NGF. Sympathetic activation further enhances inflammation and nociceptive transmission, generating a self-perpetuating feedback loop that sustains pain hypersensitivity. Arrows denote the direction of signal propagation and interaction among key mechanisms. Central sensitization represents one of the core pathological mechanisms of PBP. It is defined by increased excitability and responsiveness of central nociceptive pathways to normal or even low-threshold stimuli, reflecting maladaptive neuroplasticity and the breakdown of intrinsic inhibitory control. This maladaptive change manifests clinically as allodynia and hyperalgesia42,43. Experimental evidence from murine mild-burn models has demonstrated that neurons in the spinal dorsal horn remain hyperexcitable for several weeks after wound healing, indicating that central sensitization involves persistent plastic changes44. Similarly, in burn patients, pain frequently persists after wound closure and may spread to uninjured regions45. Upregulated NMDA receptor expression and microglial activation within the spinal cord synergistically amplify nociceptive transmission, creating a positive feedback loop that facilitates the transition from acute to chronic pain6. Transcriptomic analyses further revealed that even nonsevere burns can trigger prolonged inflammatory signalling and synaptic dysregulation in cortical excitatory neurons and microglia, providing a molecular basis for chronic pain maintenance46. Central sensitization is also associated with emotional disturbances, sleep disorders and cognitive impairment, which enhance pain perception and contribute to the persistence of chronic pain47,48. Peripheral nerve injury, which is closely intertwined with central sensitization, is another major contributor to PBP. Thermal, electrical or chemical insults directly damage peripheral nerves, producing persistent neuralgia, numbness and paraesthesia that impair both motor control and autonomic regulation. These manifestations often intensify as scar tissue forms or compresses surrounding nerves35,49. Clinical investigations have reported that approximately 6–18% of burn patients develop chronic neuropathic pain within one year of injury, which is typically associated with scar traction, nerve transection or local compression46. Peripheral nerve injury therefore acts as both a local pain source and a catalyst for central sensitization and neuroinflammatory activation, leading to heightened neural hypersensitivity. Neurogenic inflammation serves as a pivotal driver of postburn pain. Tissue damage following burn injury activates multiple inflammatory cascades, causing the release of neuropeptides and mediators such as substance P, calcitonin gene-related peptide (CGRP), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF)50,51. These factors stimulate immune cells, vascular endothelium and peripheral nerve endings, resulting in vasodilatation, increased vascular permeability and leucocyte infiltration that exacerbates both inflammation and pain. In the spinal cord, microglial TNF-α release activates the astrocytic JNK/CXCL1 pathway, increasing proinflammatory cytokine production and promoting the progression from acute to chronic pain52. In vitro burn-skin models also reveal significant upregulation of substance P and CGRP within 24 hours of injury, which induces immune-cell recruitment and amplifies inflammatory responses53. Through TRPV1 and Mrgpr signalling, these neuropeptides establish a positive feedback loop that sustains hyperalgesia and reinforces pain persistence54. Given the dynamic interplay among these mechanisms, neuromodulation, particularly long-acting approaches, may offer a means to modulate multiple interconnected pathways in a sustained manner, thereby providing a rationale for integrated therapeutic strategies. Mechanistic basis of motor dysfunction and neuromuscular degeneration Severe burns not only cause pain and sensory disturbances but also frequently result in persistent motor dysfunction, most notably generalized skeletal muscle atrophy and weakness55,56. These impairments arise from a combination of disuse-related atrophy and burn-specific neuromuscular pathology57. Prolonged immobilization and bed rest are common in patients with extensive burns, whereas pain and reconstructive procedures such as skin grafting further restrict movement, leading to rapid muscle loss due to the absence of load-bearing contractions58. Clinical observations indicate that muscle mass and strength decline significantly within weeks after severe burns59. Even years after apparent recovery, burn survivors often show residual weakness compared with healthy individuals, implying partially irreversible neuromuscular sequelae60. In addition to disuse, burn trauma elicits profound systemic stress and hypermetabolic responses. To sustain tissue repair, the body accelerates protein catabolism, resulting in enhanced skeletal muscle protein breakdown and depletion61. Experimental evidence has demonstrated that severe burns upregulate the ubiquitin ligases MuRF-1 and Atrogin-1, promoting muscle apoptosis, autophagy and atrophy62. Elevated stress hormones and burn-related insulin resistance further inhibit protein synthesis, aggravating muscle wasting63. Burn-induced neuromuscular damage represents an active neuropathological process rather than a secondary metabolic consequence. Burn-induced neuromuscular damage represents an active neuropathological process rather than a secondary metabolic consequence. Burn-related peripheral neuropathy involving both sensory and motor fibres has been reported in more than 10% of patients in a cohort of 572 individuals with major burn injuries, particularly in those with severe systemic involvement, and may persist for years. It is characterized by decreased muscle strength, reduced nerve conduction velocity on electromyography, and diminished tendon reflexes64,65. Beyond peripheral nerve involvement, burn injury also disrupts neuromuscular transmission at the synaptic level. Extensive burns additionally disrupt the integrity of neuromuscular junctions (NMJs), producing denervation-like alterations66. Within several days of injury, affected muscles exhibit abnormal clustering of acetylcholine receptors and reduced synaptic contacts between nerve terminals and muscle membranes, indicating impaired NMJ transmission. These changes are thought to result from axonal retraction and Schwann cell dysfunction at the motor endplate67. At the spinal level, severe burns trigger pronounced activation of microglia in the anterior horn. The inflammatory mediators released exert neurotoxic effects on motor neurons, causing degeneration and secondary denervation68. Consequently, muscle fibres lose normal spinal innervation, the NMJ number and function decline markedly, and progressive muscle weakness develops69. Early functional rehabilitation and physical therapy have been shown to mitigate disuse atrophy, preserve muscle strength and improve mobility70. Moreover, neuromodulation techniques targeting burn-related neuropathy have the potential to reduce motor–neuronal injury and peripheral demyelination, thereby enhancing neural regeneration and muscle protein synthesis71. Mechanistic pathways underlying hypertrophic scar formation Postburn hypertrophic scars represent an dysregulated fibrotic response during wound healing driven by dysregulated collagen metabolism, chronic inflammation and excessive fibroblast activation72. These scars are typically raised, erythematous and firm and are often accompanied by itching or pain. Clinically, three major forms are recognized: hypertrophic scars confined to the original wound, keloids extending beyond the wound margins, and contracture scars occurring in high-mobility regions, such as joints, that cause functional limitations and deformities73. Scar hypertrophy most commonly follows deep dermal or full-thickness burns and is associated with delayed healing, wound infection or high mechanical tension10. It is also more prevalent among children and individuals with darker skin or keloid predispositions74. Emerging evidence indicates that the neural system plays an active regulatory role in this process. During repair, injured nerve endings often fail to regenerate normally, whereas residual or newly sprouting fibres display disorganized hyperinnervation75. This altered or increased neural reinnervation, particularly evident in hypertrophic scars and keloids, features markedly increased nerve-fibre density around vessels, hair follicles and the subepidermal layer, which is closely correlated with pain and pruritus severity76. Immunohistochemical analyses revealed strong Substance P and CGRP staining, confirming enhanced neuropeptide expression and implicating neural involvement in scar pathogenesis77. Substance P released from sensory C fibres acts as an early mediator in the inflammatory cascade78. Through NK1R binding, it activates mast cells and macrophages to release histamine, IL-1β and TNF-α, inducing vasodilatation, exudation and fibroblast proliferation with increased collagen synthesis79. In scar tissue, Substance P directly promotes the deposition of collagens I and III while inhibiting neutral endopeptidase activity, thereby prolonging neuropeptide effects and sustaining inflammation and fibrosis80. It also contributes to pain and pruritus via the activation of limbic nociceptive circuits81. CGRP exerts phase-dependent and multifaceted effects. During the inflammatory phase, CGRP acts through RAMP1 receptors on neutrophils and macrophages to regulate polarization and apoptosis, contributing to the regulation and resolution of inflammation82. In the proliferative and remodelling phases, it stimulates fibroblast proliferation and migration, enhances collagen synthesis and extracellular-matrix reconstruction, and supports angiogenesis by inducing TSP-1 release83. Elevated CGRP concentrations have been reported in patients with painful or pruritic scars, with circulating levels correlating positively with symptom severity. However, because CGRP is primarily released locally from sensory nerve endings, circulating levels likely reflect increased neuropeptide release rather than directly representing peptide concentrations at the tissue site of action, supporting the role of CGRP as both a fibrotic regulator and a mediator of neurogenic symptoms84. Other neuropeptides, such as neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP), also participate in scar formation. NPY modulates macrophage-derived TNF-αrelease and angiogenesis, whereas VIP promotes cellular proliferation, immune regulation and matrix remodelling85,86. Both are upregulated in pathological scars and influence immune and vascular responses during the inflammatory and proliferative stages87. Although their mechanisms remain incompletely defined, their neuroimmune signalling functions warrant further investigation. Mechanical tension is recognized as a major determinant of scar progression.Clinical observations are consistent with this concept, indicating that hypertrophic scars occur more frequently in anatomical regions exposed to recurrent stretching and elevated mechanical tension, such as the sternum, joints, and lower abdomen. The anterior chest wall, particularly the sternal region, represents a typical high-risk site because it undergoes repetitive mechanical strain during respiration, upper-limb movement, and trunk extension88. Mechanical loading induces abnormal neuronal discharges and neuropeptide release, promoting fibroblast activation through neuromechanical coupling and thereby intensifying pruritus and pain89. These findings highlight that hypertrophic scar development results from multiple synergistic mechanisms that act in concert. Overall, hypertrophic scar formation arises from complex interactions among neural, immune and fibroblast networks. Persistent neuropeptide release from sensory endings activates mast cells and macrophages, amplifying inflammation; activated immune cells in turn drive fibroblast differentiation into myofibroblasts and stimulate extracellular matrix synthesis90. Fibroblast-derived TGF-β, PDGF and VEGF further promote nerve regeneration and neuropeptide release, forming a self-perpetuating feedback loop. Following injury, regeneration and sprouting of small nerve fibres represent a normal component of tissue repair; however, studies have shown that scar tissue, particularly in painful or pruritic scars, often exhibits increased density and disorganized sprouting of small sensory nerve fibres. This altered neural architecture amplifies neurogenic pain and itch, reinforcing the reciprocal cycle among neural activity, inflammation and fibrosis91. Neuromodulation enhancing wound healing and interrupting the pain cycle In addition to providing analgesia, facilitating functional rehabilitation, and modulating scar formation, neuromodulation may offer further therapeutic advantages during the acute phase of wound repair. Evidence indicates that interventions based on electrical stimulation can modulate the local bioelectrical environment and tissue repair mechanisms, thereby enhancing wound closure and improving overall healing outcomes. For burn wounds, microcurrent therapy has demonstrated the potential to reduce healing time in randomized controlled studies. For instance, in a prospective randomized trial involving paediatric patients with partial-thickness burns, the median healing time was 6 days in the wireless microcurrent stimulation group versus 8 days in the standard dressing group (p = 0.0057), supporting the hypothesis that such interventions may accelerate early wound healing92.Similarly, in a randomized controlled within-patient study of 30 individuals with acute minor burn injuries, electrical stimulation applied to one wound site significantly improved oedema resolution and accelerated healing dynamics compared with standard care alone, further supporting the therapeutic potential of microcurrent-based interventions in burn wound management93. Pulsed electromagnetic fields (PEMFs) have also been shown to improve wound-associated physiological parameters; however, most available evidence pertains to chronic rather than acute wounds. In a randomized, double-blind, placebo-controlled study of chronic diabetic foot ulcers, PEMF therapy was associated with greater wound area reduction and enhanced microcirculation. Specifically, by the end of treatment, wound area decreased by 18% in the PEMF group compared to 10% in the control group. Additionally, capillary blood flow velocity increased by approximately 28%, and capillary diameter increased by about 14% in patients receiving PEMF therapy. These findings support the potential of PEMFs to promote tissue repair, at least partly through improved local perfusion. Nevertheless, because these results are derived from chronic or disease-specific wound contexts, their applicability to acute burns or other acute wounds remains to be determined94. Beyond their effects on tissue repair, neuromodulatory interventions may also modulate early biological processes that contribute to the persistence of pain following injury. Sustained nociceptive input after trauma can induce sensitization within the spinal cord and higher-order central pain pathways, which is widely recognized as a key mechanism in the transition from acute to chronic pain. In this context, transcutaneous electrical nerve stimulation (TENS), peripheral nerve stimulation, and vagus nerve stimulation may provide benefits that extend beyond immediate symptom relief. By influencing autonomic function and inflammatory signaling, these interventions may help mitigate pain amplification during the early post-injury phase. A systematic review and meta-analysis reported that indirect vagal neuromodulation was associated with significant reductions in pain and improvements in inflammatory outcomes, with pooled effect sizes of SMD = 2.29 (95% CI, 1.08–3.50) for pain and SMD = 1.31 (95% CI, 0.45–2.18) for inflammatory markers. These data suggest that autonomic-targeted interventions could have translational relevance for limiting maladaptive pain amplification and restoring inflammatory homoeostasis, although their efficacy in preventing chronic post-traumatic pain remains to be clarified95. Collectively, current evidence indicates that low-intensity, non-invasive neuromodulation may have dual significance in acute wound management, potentially influencing both tissue repair and the trajectory of early pain. However, the existing body of evidence is constrained by substantial heterogeneity, limited study quality, and the predominance of studies conducted in non-acute or non-traumatic wound populations. Consequently, these findings should be regarded as mechanistic and translationally informative rather than as definitive guidance for clinical practice. Future high-quality mechanistic studies and rigorously designed clinical trials are needed to address key questions regarding optimal indications, stimulation parameters, timing of initiation, and treatment duration. Mechanistic and clinical evidence of neuromodulation in postburn pain management PBP evolves through distinct temporal phases, typically beginning as acute nociceptive pain and, in some patients, progressing to chronic neuropathic pain. Its complex and refractory nature continues to challenge effective clinical management. Conventional analgesic regimens primarily depend on opioids and nonsteroidal anti-inflammatory drugs (NSAIDs). However, the global opioid crisis has led recent clinical guidelines to deemphasize opioids as first-line analgesics, advocating short treatment courses, minimal dosages and multimodal multidisciplinary strategies instead96. Despite these measures, prolonged opioid use without adequate monitoring persists in some patients, heightening the risk of dependence and overdose97. Neuromodulation has emerged as a promising nonpharmacological approach that employs physical stimuli such as electrical, magnetic, or optical inputs to regulate dysregulated central and peripheral neural activity98,99. It offers favourable safety and opioid-sparing potential and can modify injury-induced neuroplasticity by engaging the gate-control mechanism and activating descending inhibitory pathways, thereby contributing to pain relief and functional recovery100. According to the delivery mode and mechanism of action, neuromodulation techniques can be broadly classified into three categories. (1) Noninvasive modalities, including repetitive transcranial magnetic stimulation (rTMS) and transcutaneous electrical nerve stimulation (TENS), modulate cortical or segmental circuits without surgical intervention101,102. (2) Invasive or minimally invasive modalities, such as SCS and peripheral nerve stimulation (PNS), provide sustained modulation of spinal and peripheral nociceptive transmission103,104. (3) Emerging experimental neuromodulation approaches, such as optogenetics, magnetogenetics, and sonogenetics, enable cell-specific control of neural circuits with high temporal and spatial precision105,106. (Figs. 2, 3). Noninvasive and invasive neuromodulation techniques for pain modulation and their anatomical targets. Neuromodulation techniques act across cortical, spinal and peripheral levels to regulate nociceptive processing. Noninvasive approaches, including repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), modulate cortical excitability and enhance descending inhibitory control, while transcutaneous electrical nerve stimulation (TENS) activates peripheral afferent fibres to engage spinal gate-control mechanisms and reduce nociceptive transmission; trans-spinal direct current stimulation (tsDCS) further modulates spinal excitability and sensorimotor integration to alleviate central sensitization. Invasive or minimally invasive techniques target deeper neural structures to achieve sustained modulation, including spinal cord stimulation (SCS), which activates dorsal column Aβ fibres via epidural electrodes to reinforce inhibitory pathways, peripheral nerve stimulation (PNS), which suppresses ectopic discharges and attenuates central sensitization, vagus nerve stimulation (VNS), which engages nucleus tractus solitarius projections and the cholinergic anti-inflammatory reflex, and deep brain stimulation (DBS), which modulates activity within the periaqueductal gray, thalamic nuclei and anterior cingulate cortex to influence both sensory and affective components of pain. Emerging neuromodulation techniques and their molecular mechanisms. Emerging neuromodulation approaches enable cell-specific and temporally precise control of neuronal activity through genetic and biophysical mechanisms. Optogenetics uses light-sensitive ion channels, such as Channelrhodopsin-2 (ChR2), to achieve millisecond-scale activation or inhibition of neurons, with blue light around 470 nm inducing rapid membrane depolarization or hyperpolarization. Magnetogenetics enables noninvasive modulation of neurons expressing magneto-responsive ion channels, including Nb-Ft-TRPV1, in which ferritin nanoparticles convert external magnetic fields into mechanical gating signals. Sonogenetics employs ultrasound-sensitive channels, such as hsTRPA1, to transduce focused ultrasound energy into calcium influx, allowing noninvasive and spatially precise modulation of deep-brain neuronal populations. Noninvasive neuromodulation techniques Noninvasive neuromodulation techniques have rapidly advanced in the management of chronic pain and neurorehabilitation. By applying external electrical, magnetic, or optical stimulation to the skin, scalp, auricle, or other body surfaces, these modalities activate or modulate specific sensory neurons, spinal pathways, or cortical regions, thereby counteracting pathological hyperexcitability in the central and peripheral nervous systems107. Representative modalities include TENS, repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and auricular vagus nerve stimulation (aVNS). These approaches are noninvasive, do not require surgery, and are associated with favourable safety profiles and strong patient acceptance108. In postburn pain and neurofunctional recovery, they provide effective adjuncts or alternatives to pharmacotherapy, particularly for patients who are intolerant of or unwilling to use opioids. During rehabilitation, they may also increase neuroplasticity, promote motor recovery, and reduce scar-related pain through synergistic modulation of central and peripheral circuits. Repetitive Transcranial Magnetic Stimulation (rTMS) rTMS is based on Faraday’s law of electromagnetic induction. A magnetic coil placed on the scalp generates short bursts of magnetic fields that induce local currents in the underlying cortex, leading to depolarization or hyperpolarization of cortical neurons and thereby modifying neuronal excitability109. The stimulation frequency determines the direction of plasticity: high-frequency rTMS (≥5 Hz) enhances cortical excitability and produces long-term potentiation (LTP)-like effects, whereas low-frequency stimulation (approximately 1 Hz) suppresses excitability and induces long-term depression (LTD)-like effects110. These modulatory effects may persist for hours to days, and repeated sessions can result in sustained cortical reorganisation, offering a therapeutic opportunity for chronic pain and functional recovery. Analgesia induced by rTMS is attributed primarily to the activation of cortically mediated descending inhibitory networks, with the primary motor cortex (M1) being the principal target111. A prospective systematic review that pooled six randomized controlled trials of central poststroke pain (n = 180) demonstrated significant pain reduction with rTMS compared with sham stimulation (standardized mean difference = −1.45; 95% CI − 1.87 to −1.03; p < 0.001), confirming its clinical efficacy. The same analysis revealed greater benefit with 20 Hz stimulation than with 10 Hz stimulation in chronic neuropathic pain, highlighting the importance of frequency optimization112. Furthermore, rTMS analgesia is closely associated with activation of the endogenous opioid system. In human studies, the analgesic effect of 10 Hz M1 stimulation was abolished by the μ-opioid receptor antagonist naloxone, while the plasma concentrations of β-endorphin and enkephalin increased significantly113. These findings suggest that rTMS modulates pain not only by inducing cortical plasticity but also by engaging the midbrain and medullary descending pathways to promote endogenous analgesic release. PBP often presents as persistent burning, scar-related, or phantom-like pain with concurrent peripheral remodelling and central sensitization. The multilayered central effects of rTMS make it a promising nonpharmacological option, particularly for patients showing poor opioid responsiveness or a risk of dependence. In patients with partial-thickness upper-limb burns involving less than 10% of the total body surface area (TBSA) and a disease duration of less than two years, a shortened cortical silent period on the affected side indicates impairment of γ-aminobutyric acid (GABA)-mediated inhibitory circuits, which may be restored by high-frequency rTMS114. In addition, rTMS can modulate limbic and associative circuits to alleviate anxiety, depression, and sleep disturbances associated with chronic pain115. Although specific data for postburn chronic pain remain limited, robust efficacy in complex regional pain syndrome (CRPS), fibromyalgia, spinal cord injury-related pain, and postamputation phantom pain provides strong mechanistic support116. In CRPS, high-frequency M1 stimulation reduces continuous pain intensity and improves limb function117. In phantom limb pain, rTMS realigns cortical body representations and decreases pain frequency and intensity. In scar-related pain, rTMS helps restore the balance of cortical excitation and inhibition within pain-affective networks, and in burning or phantom sensations, it reshapes M1–S1 connectivity to correct maladaptive feedback and pain memory118. Transcranial direct current stimulation (tDCS) tDCS delivers low-intensity direct current between scalp-mounted anodal and cathodal electrodes to modulate neuronal excitability. Anodal stimulation depolarizes neuronal membranes, thereby increasing excitability, whereas cathodal stimulation hyperpolarizes membranes and suppresses neuronal activity119. Unlike transcranial magnetic stimulation, tDCS does not directly elicit action potentials but instead induces sustained modulation of resting membrane potentials, leading to network-level plasticity that influences circuits involved in cognition, motor control, affective regulation, and pain processing120. The analgesic mechanisms of tDCS involve the modulation of descending pain control pathways projecting from the primary motor cortex (M1) to the thalamus, brainstem, and spinal cord, as well as the regulation of the affective dimension of pain via the dorsolateral prefrontal cortex (DLPFC))121. Stimulation of different cortical targets can selectively influence the sensory, affective, and cognitive components of pain. Anodal M1 stimulation enhances inhibitory interneuron activity and indirectly suppresses nociceptive transmission within the spinal dorsal horn, whereas anodal prefrontal stimulation modulates chronic pain–related affective responses and attentional bias122. Clinical research on tDCS for postburn pain remains limited but promising. In a prospective randomized double-blind trial, cathodal tDCS applied to the contralateral primary somatosensory cortex for 20 minutes daily over several days significantly reduced both pain and anxiety during dressing changes compared with sham stimulation123. Another study involving sixty patients with severe burns reported that a single 20-minute session of one-milliampere cathodal tDCS reduced pain–anxiety scores from 29.3 to 23.4 and relieved pruritus124. Recent findings also indicate that alpha-band transcranial alternating current stimulation (tACS) can enhance somatosensory alpha oscillations and attenuate experimentally induced chronic pain, supporting the concept of rhythm-coupled analgesia125. In a randomized, double-blind, crossover study involving 31 patients with burn injury, motor cortex (M1) tDCS did not show superior analgesic effects compared with sham stimulation, whereas itch scores decreased spontaneously in the sham group during follow-up126. These findings suggest that the modulation of burn-related pain and itch may not rely solely on motor cortical networks, underscoring the importance of precise target selection, such as in the primary somatosensory, parietal sensory, and prefrontal regions. A systematic review and meta-analysis of 16 randomized controlled trials demonstrated that anodal tDCS significantly reduced pain scores in patients with fibromyalgia (standardized mean difference ≈ 1.2; 95% confidence interval 0.8–1.7; p < 0.001), with greater efficacy observed in protocols lasting ≥ 4 weeks127. Although not specific to burn injury, these findings provide valuable insight into the long-term neuromodulatory management of chronic pain and associated psychosocial comorbidities. tDCS offers notable advantages, including portability, ease of use, and a favourable safety profile, which allow for long-term application in both clinical and home settings. Daily home-based protocols have demonstrated good adherence and sustained analgesic benefits. For patients undergoing burn rehabilitation, this noninvasive, parameter-adjustable, and well-tolerated technique represents a feasible strategy for managing chronic scar pain, pruritus, and mood disturbances128. Nevertheless, therapeutic outcomes depend heavily on electrode placement, polarity, current intensity, session duration, and frequency. At present, standardized stimulation parameters for distinct postburn pain phenotypes remain undefined, and most clinical data rely on subjective scales rather than objective neurophysiological or imaging-based endpoints129. Future research should therefore aim to identify optimal targets and parameters, integrating functional neuroimaging, cortical excitability mapping, and affect–function correlations to develop predictive and evaluative frameworks for tDCS-based interventions. Transcutaneous vagus nerve stimulation (tVNS) tVNS is a noninvasive technique that activates auricular or cervical branches of the vagus nerve to modulate central neural and immune activity, producing both analgesic and anti-inflammatory effects130. Compared with implanted systems, tVNS uses surface electrodes, does not require surgery, and can be easily applied in clinical or home-based environments. Owing to its simplicity, safety, and wide applicability, tVNS has attracted increasing interest for chronic pain, inflammatory disorders, and mood-related conditions131. Mechanistically, afferent fibres from auricular or cervical vagal branches project to the nucleus tractus solitarius (NTS) and subsequently to the periaqueductal gray, locus coeruleus, hypothalamus, amygdala, and anterior cingulate cortex. These interconnected regions participate in the regulation of pain perception, emotional processing, and autonomic function132. The efferent vagal pathways activate the cholinergic anti-inflammatory reflex, in which acetylcholine binds to α7 nicotinic acetylcholine receptors on immune cells and inhibits the release of proinflammatory cytokines, including tumour necrosis factor-α, interleukin-1β, and interleukin-6, thereby reducing systemic inflammation133. A recent meta-analysis including approximately fifteen randomized controlled trials involving patients with chronic pain demonstrated that tVNS significantly reduced pain intensity compared with that in control groups, with a moderate pooled effect size (Hedges’ g ≈ 0.41, 95% CI 0.17–0.66) and no serious adverse events reported. Subgroup analyses indicated comparable benefits for auricular and cervical stimulation, both of which had small-to-moderate effects (0.36–0.42). These findings suggest that tVNS provides consistent analgesia across diverse chronic pain syndromes, such as migraine, fibromyalgia, and temporomandibular disorders, although heterogeneity among studies remains considerable134. Neuroimaging research further indicates that tVNS enhances functional connectivity between the prefrontal cortex and default mode network while reducing depressive and anxiety symptoms, supporting its dual action on pain and mood regulation135,136. Preclinical evidence also supports these effects. In a rat model of severe burns, early auricular vagus nerve stimulation within six hours after injury accelerated gastric emptying and alleviated burn-induced gastrointestinal dysmotility by inhibiting sympathetic overactivation through the cyclooxygenase-2 and norepinephrine pathways137. These findings suggest that vagal activation may provide systemic protection in the acute postburn phase. Nevertheless, clinical evidence specific to burn populations is still limited. Current reviews indicate that well-designed randomized trials of neuromodulation interventions in burn medicine remain scarce both in China and globally138. During long-term recovery, tVNS may modulate descending inhibitory and limbic circuits to regulate pain, mood, and autonomic function, thereby alleviating scar-related pain and pruritus. Its wearable, portable, and noninvasive characteristics make it particularly suitable for long-term, home-based integrative management. Transcutaneous electrical nerve stimulation (TENS) and scaffold therapy TENS is one of the most established noninvasive neuromodulation techniques used in clinical pain management. Low-frequency pulsed electrical currents delivered through surface electrodes selectively activate large-diameter Aβ fibres, which can inhibit nociceptive transmission from C and Aδ fibres through spinal inhibitory mechanisms that are consistent with the gate-control theory of pain modulation139,140. Beyond spinal gating, TENS enhances endogenous analgesic mechanisms by promoting the release of β-endorphins, norepinephrine, and serotonin within the spinal cord and brain, thereby strengthening descending inhibitory control and producing sustained analgesia141. Its simplicity, safety, and reproducibility have led to its broad application in musculoskeletal, postoperative, and neuropathic pain, providing both theoretical and clinical foundations for managing burn-related pain syndromes. Clinical evidence supports TENS as a safe and effective adjunctive therapy for burn pain. In an open-label pilot study involving patients with second- and third-degree burns, a combination of continuous and intermittent TENS administered three times per week for four weeks (30 minutes per session) significantly reduced the mean VAS pain score from 8.0 ± 1.7 at baseline to 1.0 ± 0.5 on day 30, with no adverse events reported142. These results demonstrate the potential of TENS to alleviate both nociceptive and neuropathic components of burn pain. For chronic neuropathic pain, the TENS principle has evolved into Scrambler therapy, which delivers specifically encoded random waveforms to peripheral nerves through cutaneous electrodes. By transmitting synthetic “nonpain” information, this method replaces maladaptive nociceptive signals with nonpainful input and reorganizes pain perception networks143. These findings indicate that Scrambler Therapy may modulate both the sensory and affective dimensions of postburn pain through cortical plasticity. Experimental studies further confirmed the parameter-dependent efficacy of TENS. High-frequency TENS (80 to 100 Hz) elevates both heat and mechanical pain thresholds in healthy volunteers, with stimulation frequency and intensity determining the degree of hypoalgesia144. Besides, a large-scale systematic review and meta-analysis encompassing 381 studies and approximately 25,000 participants demonstrated that pain intensity was consistently lower during or immediately after TENS than after placebo, with minimal adverse events145. Prior postoperative trials also confirmed that TENS reduces opioid use, facilitates early mobilization, and improves recovery. Collectively, these results support TENS as a safe, nonpharmacological, and opioid-sparing component of multimodal pain management in burn rehabilitation. Beyond general analgesic effects, TENS has also been explored in specific postburn complications, particularly in the management of postburn phantom limb pain. In transtibial amputees, the use of high-density electrode arrays over distal sciatic nerve branches successfully evoked plantar tactile sensations and reduced phantom pain intensity in all participants, indicating that targeted peripheral stimulation can retrain somatosensory representations and mitigate phantom sensations146. Other clinical observations have shown that in burn patients with inhalation injury, early Acu-TENS can significantly improve pulmonary function, including increases in FVC, FEV₁, and diaphragmatic mobility, compared with standard respiratory therapy alone. Although systemic inflammatory markers were not evaluated in this cohort, these findings suggest that acupoint-directed electrical stimulation may influence autonomic activity and immune regulation147. This approach may therefore serve as a potential adjunctive therapy to support multisystem recovery after severe burns. Functional electrical stimulation (FES) FES applies pulsed electrical currents through surface or implanted electrodes to elicit contractions in target motor nerves or muscles, thereby restoring voluntary functions such as grasping, standing, walking, or respiratory support. When combined with task-oriented movement training, FES provides immediate compensatory muscle activation and, through repetitive stimulation, facilitates corticospinal plasticity and long-term motor recovery148. The activation of Ia afferent fibres indirectly engages the motor cortex to induce synaptic reorganization and promote neuroregeneration. Repeated contractions also prevent disuse atrophy, enhance local perfusion, and maintain joint mobility149. In addition to improving motor outcomes, FES can increase segmental thresholds to nociceptive input and activate descending inhibitory pathways, leading to relief from chronic neuropathic pain. Its analgesic and rehabilitative efficacy has been demonstrated in various neurological conditions, including the reduction of poststroke shoulder pain and improvement in joint mobility150, as well as the enhancement of strength and circulation with reduced pain sensitivity in patients undergoing SCI rehabilitation151,152. Although randomized controlled trials in burn populations remain limited, accumulating evidence indicates that FES is both safe and potentially effective in burn rehabilitation. In a pilot study, combined continuous and intermittent electrical stimulation applied around burn regions for four weeks significantly alleviated pain during dressing changes without adverse effects142. Complementary findings from preclinical and clinical studies using pulsed electromagnetic fields (PEMFs) or ES in burn and complex wound models demonstrated accelerated resolution of oedema, enhanced epithelialization, and improved local microcirculation, suggesting that such interventions may promote angiogenesis and tissue regeneration153,154. However, high-quality randomized controlled trials evaluating combined ES–PEMF interventions in acute burn wounds remain scarce, and further studies are warranted to substantiate their potential synergistic benefits. Furthermore, systematic reviews and meta-analyses encompassing chronic and complex wound populations have shown that adjunctive ES significantly shortens healing duration, reduces oedema and bacterial burden, and decreases infection risk compared with standard care, with minimal adverse events and overall moderate-quality evidence154,155. Although most evidence originates from nonburn wound populations, these consistent findings suggest the translational importance of electrical stimulation as a safe and low-risk adjunct modality. Its application may promote wound repair, relieve pain, and enhance functional recovery during burn rehabilitation. Minimally invasive or invasive neuromodulation Minimally invasive and invasive neuromodulation modalities have been developed to address complex clinical conditions such as refractory pain, profound motor impairment, and autonomic dysfunction, particularly in patients unresponsive to noninvasive interventions156. Unlike surface stimulation methods, these systems involve the surgical implantation of electrodes or probes that deliver targeted electrical impulses to specific neural circuits, allowing for precise and sustained modulation of central or peripheral nervous activity157. Representative approaches include implanted VNS, SCS, DBS, and PNS158. Although implantation procedures are associated with increased cost and surgical risk, these modalities have demonstrated substantial efficacy in the management of chronic neuropathic pain, complex regional pain syndrome, and postamputation pain. Emerging reports also suggest potential benefits for refractory postburn pain and scar traction pain, indicating their expanding role in comprehensive burn rehabilitation. Implanted vagus nerve stimulation Implanted VNS is performed by surgically wrapping a stimulating electrode around the left cervical vagus nerve and connecting it to a subcutaneous pulse generator in the chest wall, thereby delivering intermittent stimulation to vagal afferents. Compared with transcutaneous approaches, implanted VNS provides programmable, durable output with well-established clinical evidence159. Afferent signals ascend to the nucleus tractus solitarius and then to limbic structures, the thalamus, hypothalamus and prefrontal cortex, supporting the modulation of descending antinociceptive and emotion-related circuits159. On the other hand, acetylcholine activation of α7 nicotinic receptors initiates the cholinergic anti-inflammatory pathway, which inhibits TNF-α, IL-1β, and IL-6 production and contributes to neuroimmune regulation160,161. After burn injury, VNS has shown systemic anti-inflammatory and organ-protective potential. In a rat model of severe thermal injury, intermittent VNS reduced vascular permeability at 24 h and attenuated oedema and inflammatory infiltration in the skin and lungs while protecting gut barrier integrity and reducing intestinal permeability. Additional work has revealed increased enteric glial activation, preservation of tight junction proteins, and limits to endotoxin translocation, which is consistent with protection of the endothelial and epithelial barriers162. Although formal burn-specific clinical trials are lacking, the application of VNS in the treatment of inflammatory disorders and neuropathic pain provides a translational rationale. Multiple reviews indicate that VNS can increase pain thresholds by engaging descending inhibitory networks (e.g., the locus coeruleus and periaqueductal gray) and by modulating endogenous opioids163,164. Given the invasiveness of implantation, candidates should be clinically stable and appropriate for anaesthesia and postoperative care. In the acute burn phase, profound hypermetabolic stress and infection risk argue against implantation; VNS is better considered for refractory chronic scar-related pain after failure of conservative therapies and noninvasive neuromodulation165. Spinal cord stimulation SCS is an established invasive neuromodulation technique in which multichannel electrodes are implanted epidurally over the dorsal columns and connected to a pulse generator that delivers controlled electrical impulses to modulate dorsal column and dorsal horn activity166. Stimulation primarily activates large-diameter Aβ fibres, which suppress nociceptive transmission from C and Aδ fibres through spinal gating mechanisms. In addition, SCS enhances the release of inhibitory neurotransmitters such as γ-aminobutyric acid (GABA), noradrenaline, and serotonin within the dorsal horn and engages in descending antinociceptive pathways involving the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and locus coeruleus, thereby modulating both ascending and descending pain processing167. SCS has demonstrated robust efficacy in managing refractory neuropathic pain, including complex regional pain syndrome (CRPS), diabetic neuropathy, and failed back surgery syndrome, with support from large multicenter randomized trials. Advances in stimulation paradigms have diversified traditional 50 Hz tonic stimulation into high-frequency (10 kHz) SCS, burst SCS, and closed-loop SCS168. In the SENZA randomized controlled trial for chronic back and leg pain, 10 kHz SCS achieved a ≥ 50% pain reduction in 67–70% of participants at 12 months, compared with 44–49% for conventional SCS, and reduced or discontinued opioid use in approximately 38% of patients, highlighting its opioid-sparing capacity169. The Evoke trial further demonstrated that closed-loop SCS, which automatically adjusts stimulation on the basis of real-time evoked compound action potentials, provides more stable pain relief, extends the therapeutic window, and improves sleep, mood, and quality of life while minimizing paraesthesia-related discomfort170. Although clinical reports in burn survivors are limited, the available case studies indicate promising outcomes. In one case report, a 67-year-old man with persistent refractory pain in the left lateral abdominal and gluteal regions following burn injury achieved substantial pain reduction after spinal cord stimulation implantation, enabling complete discontinuation of opioid therapy and long-term relief171,172. A trial and subsequent permanent SCS implantation both resulted in a substantial reduction in VAS pain scores and complete discontinuation of opioids173. Emerging SCS modalities have expanded clinical applicability. Burst SCS has maintained two-year pain relief in CRPS patients after waning efficacy of tonic stimulation, with numeric rating scale (NRS) scores decreasing from 8 to 2, suggesting durable modulation of central pain circuitry174. Dorsal root ganglion stimulation (DRG-S) offers precise targeting of single ganglia, enabling localized control of focal neuropathic pain with fewer adverse effects, making it particularly relevant for postburn scar pain, residual limb pain, and phantom sensations175. The integration of closed-loop SCS with wearable sensor systems, such as pressure-sensing insoles, has also been shown to restore plantar sensory feedback in amputees, improve gait and postural stability, and reduce phantom pain intensity by more than 50%, underscoring its potential in functional restoration and sensory rehabilitation176. Although surgical risks such as lead migration, infection, and epidural haematoma are present, these complications are generally well characterized and largely manageable within contemporary clinical practice, allowing health-economic analyses to focus on broader outcomes.Health-economic analyses indicate that SCS can substantially reduce long-term healthcare expenditures and improve quality-adjusted life years (QALYs) across chronic pain conditions177. Real-world studies further report meaningful reductions in opioid consumption, with approximately 15–20% of patients achieving complete discontinuation within one year following implantation. Collectively, these findings support SCS as a cost-effective and opioid-sparing strategy for managing refractory neuropathic pain, offering potential translational value for chronic postburn pain rehabilitation178. Deep brain stimulation DBS is a highly precise neurosurgical technique in which electrodes are stereotactically implanted into specific brain nuclei and connected to a subcutaneous pulse generator that delivers continuous high-frequency electrical stimulation. This direct modulation of pathological neural circuits allows DBS to normalize abnormal neuronal activity and restore functional connectivity within the targeted network179. Owing to its capacity for focal and adjustable modulation, DBS has been widely applied in Parkinson’s disease, dystonia, essential tremor, and certain psychiatric disorders, such as treatment-resistant depression and obsessive‒compulsive disorder. In recent years, its therapeutic applications have been extended to chronic and neuropathic pain, with promising results180. The analgesic mechanisms of DBS vary depending on the stimulation site. Stimulation of the periaqueductal gray (PAG) or medullary raphe nuclei activates descending antinociceptive pathways and suppresses nociceptive transmission within the spinal cord. Thalamic targets such as the centrolateral and mediodorsal nuclei attenuate abnormal relay activity and decrease nociceptive signalling to cortical regions. Stimulation of limbic and motivational circuits, including the anterior cingulate cortex, insula, and internal segment of the globus pallidus, modulates affective and cognitive dimensions of pain and mitigates the reciprocal enhancement between persistent pain and emotional distress181. Collectively, these effects enable DBS to influence both the sensory-discriminative and emotional-affective processing of pain. DBS was first introduced for intractable pain syndromes such as cancer pain and phantom limb pain in the 1970s. However, early applications were constrained by suboptimal electrode design, limited imaging guidance, and technological instability, which produced variable clinical outcomes182. With advances in neuroimaging, stereotactic accuracy, and stimulation parameter optimization, DBS has re-emerged as a viable option for refractory pain conditions. A comprehensive systematic review of forty-three studies involving 966 patients with chronic pain reported a standardized mean difference of approximately 1.65, indicating moderate to large analgesic effects183. Although the evidence supporting DBS in chronic pain is expanding, its use for burn-related pain remains largely unexplored. To date, no clinical trials have evaluated DBS specifically in patients with postburn pain. Most burn-associated pain, including acute procedural pain and chronic scar pain, can be adequately managed through pharmacotherapy, physical rehabilitation, and peripheral or spinal neuromodulation. The invasive nature, substantial cost, and intensive perioperative requirements of DBS further restrict its routine use in burn rehabilitation184. Moreover, posttraumatic stress disorder, anxiety, and depression are common comorbidities among burn survivors and may interact bidirectionally with DBS outcomes, highlighting the need for comprehensive neuropsychological assessment before implantation185. In exceptional cases of amputation or long-standing phantom limb pain that is refractory to conventional and semi-invasive therapies, DBS may be considered an experimental intervention. Case reports and small series of phantom limb pain have demonstrated that stimulation of the somatosensory thalamus or periaqueductal/periventricular gray matter can reduce pain intensity by approximately 50–70%, with relief sustained for up to three years, suggesting potential clinical relevance for chronic neuropathic pain following severe trauma (Abreu et al., 2017)186. Peripheral nerve stimulation PNS is a minimally invasive neuromodulation technique primarily used to alleviate focal neuropathic pain. Fine electrodes are implanted percutaneously or surgically adjacent to the target peripheral nerve or its associated ganglion, selectively activating large myelinated Aβ fibres. This activation suppresses dysregulated discharges from nociceptive C and Aδ fibres and produces analgesia, which is consistent with the gate-control theory of pain modulation187. Early applications of peripheral nerve stimulation (PNS) were directed primarily toward the occipital, trigeminal, and brachial plexus neuralgias. With advances in device miniaturization, programmable current delivery, and imaging-guided lead placement, its indications have progressively expanded to encompass a broader spectrum of neuropathic and postsurgical pain syndromes188. In amputees with long-standing neuropathic pain that remains refractory to conventional and semi-invasive interventions, percutaneous PNS has demonstrated clinically meaningful benefits. In a multicenter, randomized, placebo-controlled trial evaluating 60-day percutaneous PNS, 67% of participants achieved at least a 50% reduction in pain intensity at twelve months, with no serious device-related adverse events reported189. A subsequent twelve-month follow-up study confirmed the durability of these findings, showing sustained analgesic effects in a comparable proportion of treated amputees190. Multiple feasibility studies and early-phase clinical trials also suggest that short-term PNS can reduce opioid consumption and improve functional capacity and pain interference, although the magnitude of these effects varies, and detailed opioid-reduction metrics remain inconsistently reported. These findings indicate that the PNS provides reliable analgesic benefits across various forms of peripheral neuropathic pain and establish an important conceptual basis for extending its application to neuropathic conditions arising from other types of peripheral nerve injury191,192. In postburn conditions, progressive scar formation may infiltrate or compress peripheral nerves, resulting in chronic neuropathic pain characterized by burning, stabbing, or allodynic sensations distributed along dermatomal territories193. Although no clinical trial has specifically investigated the PNS following scar release or skin grafting in burn patients, the PNS has demonstrated efficacy under comparable conditions, such as compression-induced neuropathic pain and postamputation residual or phantom limb pain. The evidence from these studies indicates that the PNS can effectively modulate dysregulated peripheral nerve activity, attenuate ectopic discharges, and restore somatosensory balance194. Therefore, the PNS may represent a promising adjunctive strategy in burn rehabilitation to relieve localized neuropathic pain and facilitate functional recovery. Recent developments in fully implantable wireless PNS systems, which use an external skin-coupled coil to power the internal receiver, have eliminated the need for transcutaneous leads, thereby reducing infection and lead-fracture risks while improving comfort and usability for long-term applications. These technological advances make PNS a practical and sustainable option for managing chronic postburn neuropathic pain195. Moreover, the integration of the PNS with motor rehabilitation is gaining increasing attention. For example, stimulation of the common peroneal nerve can correct foot drop and improve gait stability, whereas wrist or radial nerve stimulation can facilitate hand motor recovery when peripheral denervation occurs after burn injury, thereby extending the therapeutic scope of PNS from pain control to motor restoration within comprehensive burn rehabilitation programs188,196. Emerging neuromodulation techniques These emerging technologies remain largely experimental but provide valuable insights into circuit-specific modulation of pain pathways and potential future therapeutic strategies. Emerging neuromodulation techniques represent the convergence of modern neuroscience and bioengineering. Their primary goal is to achieve precise regulation of neural activity with higher spatial and temporal resolution, greater selectivity, and lower invasiveness197. Representative methods that include optical, chemical, magnetic, and acoustic genetics have been developed to overcome the limitations of traditional electrical stimulation, which often relies heavily on anatomical placement and produces nonspecific neural activation. These approaches allow interventions directed at specific cell types, neural circuits, or molecular mechanisms, and they show considerable promise for both basic research and clinical translation. Although most of these technologies are still in the stages of animal experimentation or early clinical validation, their potential in chronic pain modulation has attracted increasing attention. Clinical data regarding postburn pain management remain scarce. However, compared with conventional electrical or pharmacological approaches, these emerging methods can target specific nodes of pain circuits without affecting nonrelevant cells. This selective modulation offers a potential avenue for addressing persistent postburn and chronic scar pain, which are characterized by high heterogeneity and complex pathophysiology. Optogenetics Optogenetics enables precise, reversible, and millisecond-scale control of neuronal or glial activity by genetically introducing light-sensitive ion channels or pumps into target cells. Representative optogenetic actuators include the excitatory channelrhodopsin-2 (ChR2), the inhibitory chloride pump halorhodopsin (NpHR), the proton pump eNpHR3.0, and the bistable channel SwiChR. When illuminated with specific wavelengths, these proteins induce rapid membrane depolarization or hyperpolarization, allowing cell type- and temporally specific activation or inhibition of defined neural populations197. Optogenetics has been widely applied to dissect nociceptive circuits and elucidate analgesic mechanisms. For example, photoactivation of serotonergic neurons in the brainstem expressing ChR2 increases c-fos expression and lowers mechanical and thermal pain thresholds in mice. In contrast, stimulation of inhibitory neurons within the anterior cingulate cortex (ACC) suppresses pain-related behaviours and selectively modulates the responses of thalamic relay neurons to distinct pain modalities198. In addition to sensory pathways, optogenetics has provided crucial insights into the affective–emotional dimension of pain. Inhibiting corticotropin-releasing factor (CRF)-positive neurons in the central amygdala (CeA) via light-sensitive chloride or proton pumps significantly alleviates anxiety- and depression-like behaviours associated with chronic pain, indicating that precise modulation of CeA circuits can attenuate the emotional amplification of nociception199. Similarly, in inflammatory pain models, optogenetic activation of excitatory neurons in the somatosensory cortex (SSC) reverses the analgesic effects of electroacupuncture via CaMKIIα-dependent signalling, linking cortical plasticity to pain modulation200. Recent studies have extended these approaches to glial populations. The expression of the red-light-sensitive channel ReaChR in spinal microglia and subsequent activation by red illumination are sufficient to induce chronic pain hypersensitivity, accompanied by increased IL-1β and c-fos expression. This hypersensitivity can be reversed by an IL-1 receptor antagonist, demonstrating that optogenetic activation of spinal microglia can drive neuroinflammation and central sensitization201. Burn injuries frequently produce complex sensory disturbances, including burning pain, allodynia, pruritus, and dysesthesia, arising from peripheral hyperexcitability and spinal–cortical sensitization202. Hypothetically, introducing inhibitory opsins such as SwiChR or eNpHR3.0 into neuromas, regenerating nerve endings, or dorsal horn neurons could enable transcutaneous optical modulation to suppress dysregulated excitatory activity and alleviate chronic postburn pain or pruritic scars. Furthermore, combining optogenetic control with stem cell transplantation may guide axonal outgrowth and regulate neuronal rhythmic activity, offering a potential strategy for restoring peripheral nerve function after severe burns. Magnetogenetics Magneticogenetics employs engineered magnetosensitive ion channels, most notably the anti-ferritin nanobody–TRPV1 fusion (Nb-Ft-TRPV1), to enable remote modulation of neuronal activity through external magnetic fields with deep tissue penetration. This strategy links TRPV1 to endogenous ferritin via a nanobody, allowing channel activation or inhibition without optical fibres or implanted leads, and thus offers a wireless approach for structures where illumination or electrode placement is impractical203. Magnetic fields penetrate biological tissues without attenuation, making this method theoretically suitable for identifying deep nociceptive targets relevant to postburn pain204. Recent studies have demonstrated functional magnetogenetic control within pain circuits. In a preclinical mouse model, AAV2-retro delivery of an excitatory Nb-Ft-TRPV1 construct to peripheral sensory neurons resulted in robust behavioural and molecular responses when direct magnetic fields were applied. Mechanical thresholds are decreased, animals avoid the magnetic zone, and c-fos expression is increased in the dorsal root ganglia and in pain-related cortical regions, indicating the activation of nociceptive pathways205. In contrast, a chloride-permeable inhibitory construct (Nb-Ft-TRPV1-Cl⁻) demonstrated antinociceptive activity in a magnetogenetic pain model. Under a controlled magnetic stimulus, expression of this variant increased withdrawal thresholds, induced place preference toward the magnetic zone, and reduced c-fos activity in the dorsal root ganglia, indicating effective suppression of peripheral nociceptor excitability205. In a separate study examining central motor circuits, the same chloride-gating variant decreased c-fos levels and altered behavioural output in freely moving mice203. These findings align with previous magnetogenetic work in motor circuits, where Nb-Ft-TRPV1 enabled bidirectional magnetic regulation of neuronal excitability and circuit output with stable viral expression203. Together, these data indicate the feasibility of long-term, wireless neuromodulation through ferritin-targeted TRPV1 channels. Although magnetogenetics has not yet been applied in burn injury or cutaneous regeneration models, its ability to modulate large tissue volumes and deep structures without implants provides conceptual advantages for heterogeneous postburn pain. Current evidence remains limited to animal studies, and translation will require detailed evaluation of viral tropism, magnetic field dosimetry, safety, and functional outcomes. Sonogenetics Sonogenetics enables remote and temporally precise control of neuronal activity through ultrasound stimulation of genetically introduced mechanosensitive channels such as MscL-G22S, TRPV1, or TRPA1 variants. Ultrasound provides high tissue and skull penetration with excellent spatial resolution, allowing millisecond-scale modulation without the use of implantable electrodes or optical fibres206. Experimental data indicate that neurons expressing humanized TRPA1 (hsTRPA1) exhibit robust calcium influx and action potential generation in response to low-intensity ultrasound pulses of approximately 100 ms, whereas these effects are attenuated by TRPA1 antagonists, confirming the specificity and safety of this approach207. Given that therapeutic ultrasound has already been used clinically to promote wound healing and scar remodelling, the integration of sonogenetic control into such protocols may provide synergistic benefits208. Expressing mechanosensitive channels within the sensory fibres of scar tissue followed by low-intensity focused ultrasound could suppress itch and burn pain while enhancing local perfusion and tissue remodelling, offering a coordinated strategy for both analgesia and regenerative repair209,210. Rehabilitation training and neuromuscular education Rehabilitation training and neuromuscular reeducation are pivotal for functional recovery following burn injury. Systematic and staged exercise interventions, when combined with neuromodulation approaches, can restore muscle strength, joint mobility, motor coordination, and neuromuscular control. These interventions prevent disuse atrophy and scar contracture and ultimately restore the ability to perform daily and occupational activities. In clinical burn management, wound closure represents only an early milestone, as deep tissue injuries are frequently accompanied by impaired motor nerve conduction, muscle wasting, sensory deficits, and scar adhesions, all of which severely affect quality of life211. Thus, rehabilitation training and neuromuscular reeducation are indispensable components of postburn functional reconstruction and are essential for preventing long-term disability, improving psychological outcomes, and enhancing treatment adherence, particularly after deep partial-thickness and full-thickness burns212 (Fig. 4). Multidimensional synergistic effects of neuromodulation in postburn rehabilitation. Neuromodulation facilitates postburn recovery through coordinated regulation at cortical, spinal, and sensory–perceptual levels. Repetitive transcranial magnetic stimulation enhances motor cortical excitability and promotes adaptive reorganization of descending motor pathways. Functional electrical stimulation activates peripheral motor units, preserves muscle metabolism, and reinforces afferent sensory feedback to the central nervous system. Virtual reality and mirror-based interventions restore proprioceptive representations and modulate pain perception through multisensory integration. Together, these approaches improve muscle performance, increase joint mobility, and accelerate overall functional restoration. Conventional rehabilitation programs include early physical therapy and functional exercises such as range-of-motion training, progressive resistance strengthening, and aerobic conditioning, as well as post-ural management and splinting to maintain joint mobility and reduce the risk of contracture formation213. Evidence indicates that structured exercise training enhances muscle strength, cardiorespiratory endurance, and flexibility while reducing oedema, joint stiffness, and the need for later reconstructive surgery214. Randomized and longitudinal studies in severely burned children further demonstrated that a 12-week combined aerobic and resistance exercise program increased lean body mass by approximately 6–7% and improved overall functional capacity, with sustained benefits lasting one to two years after discharge215. However, during the acute phase, severe pain, wound exposure, and intensive care constraints often limit voluntary activity. Under such conditions, integrating neuromodulation into rehabilitation can provide active stimulation to muscles and nerves even when voluntary movement is not feasible, thereby increasing overall training efficacy216. Neuromuscular electrical stimulation (NMES) delivers low-frequency currents through surface electrodes to activate peripheral motor nerves and induce targeted muscle contractions, thereby maintaining strength, preventing disuse atrophy, and preserving muscle mass. In patients who are immobilized or bedridden due to extensive burns, NMES serves as a passive yet effective substitute for voluntary exercise217. Compared with standard care, evidence from critically ill and mechanically ventilated populations shows that NMES can attenuate muscle atrophy, preserve quadriceps thickness, and improve muscle strength218. Randomized controlled trials further indicate that NMES reduces the incidence of ICU-acquired weakness and improves Medical Research Council (MRC) scores, which supports its potential role in preventing polyneuromyopathy and facilitating early mobilization during periods of profound immobility219. Although dedicated clinical studies in severe burn populations remain limited, findings from critical care settings are highly relevant. Extensive burns often require prolonged immobilization, deep sedation, and frequent surgical procedures, and these conditions closely resemble the factors that drive rapid muscle wasting in the intensive care environment220. Therefore, incorporating NMES into the acute phase of burn rehabilitation may help preserve neuromuscular function when voluntary activity is significantly restricted by pain, wound exposure, and intensive care constraints. Functional electrical stimulation (FES) extends the concept of NMES by synchronizing stimulation with specific functional tasks to assist movement221. Building on this task-oriented framework, studies in neurological rehabilitation have shown that FES targeting the wrist and finger extensors can facilitate active hand-opening exercises and enhance voluntary motor control, even in patients with significant upper-limb impairment. Evidence from stroke rehabilitation demonstrates that stimulation of the finger extensors improves active hand opening, supports functional task practice, and enhances upper-limb motor performance222,223. Systematic reviews further indicate that FES helps preserve the joint range of motion, reduces spasticity, and promotes sensorimotor cortical reorganization during motor recovery224. Although dedicated clinical trials in burn patients remain limited, these findings suggest that FES principles may be applicable to burn-related hand impairments such as tendon adhesions or residual weakness. In clinical scenarios where peripheral nerve injury or deep full-thickness scars reduce the penetration of electrical currents, the effectiveness of NMES may be limited. Functional magnetic stimulation (FMS) offers a noninvasive alternative in which rapidly changing magnetic fields are used to induce secondary electrical currents that trigger muscle contractions. A randomized controlled trial in critically ill patients reported that FMS helped preserve thigh muscle thickness and attenuated disuse atrophy during prolonged immobilization, suggesting potential advantages in populations at high risk for severe muscle wasting225. While these early findings are promising, burn-specific clinical trials remain unavailable, and larger studies are needed to determine the efficacy and safety of FMS in severe burn rehabilitation. Burn injury may also transiently impair central motor plasticity. A longitudinal study using transcranial magnetic stimulation demonstrated that cortical excitability and plasticity were significantly reduced at approximately six weeks after burn injury, with partial recovery observed by twelve weeks, accompanied by improvements in functional performance226. These observations suggest that a temporary reduction in cortical adaptability occurs during the early phase after burn injury, and neuromodulatory interventions that enhance cortical reorganization may help support motor recovery when combined with conventional rehabilitation. After severe burns, systemic catabolism and prolonged immobilization markedly aggravate skeletal muscle wasting. Burn-related peripheral neuropathy, scar contracture, and reduced cutaneous and proprioceptive input from affected limbs are further associated with long-term balance impairments, altered gait, and diminished motor coordination227. Accordingly, modern rehabilitation strategies increasingly incorporate sensory feedback and neuromuscular retraining to help reestablish cortical control of affected limbs. Proprioceptive tendon vibration at specific frequencies can elicit vivid kinaesthetic illusions and reflex-mediated muscle contractions, thereby providing augmented sensory input that helps maintain activation within sensorimotor pathways during immobilization or early recovery228. A recent randomized crossover pilot study involving immobile patients with deep burns affecting more than 30% of the total body surface area demonstrated that two weeks of vibration-based illusory movement training significantly increased the oxidative phosphorylation capacity of vastus lateralis mitochondria, despite no measurable changes in whole-body metabolic parameters229. The intervention was feasible and safe for bedridden patients unable to perform active exercise, although its direct effects on functional recovery require confirmation in larger controlled trials230. In addition to proprioceptive stimulation, rehabilitation strategies that focus on central neuroplasticity have received increasing attention in chronic pain research. Graded motor imagery (GMI) is among the most widely investigated approaches within this area. This intervention is commonly delivered through a structured sequence, including laterality recognition, motor imagery, and mirror therapy. The main goal is to engage sensorimotor networks on the affected side while keeping pain provocation to a minimum. Randomized controlled trials have shown that GMI can reduce pain intensity and improve functional outcomes in individuals with complex regional pain syndrome and phantom limb pain. Cross-over research also demonstrates that the initial motor imagery phase, performed even without actual limb movement, leads to reductions in neuropathic pain scores. These observations support a role for cortical sensorimotor processing abnormalities in the maintenance of persistent pain231,232. Within this therapeutic framework, mirror therapy is typically introduced in the later stages. Patients observe the mirror reflection of their unaffected limb to receive visual input that mimics normal movement of the affected side. When compared to standard physical therapy, GMI has shown some advantage in reducing pain, which highlights the potential value of mirror therapy and the broader graded rehabilitation approach for chronic pain management. Despite these promising findings, the current evidence base is limited and most studies are small in scale. Consequently, the independent effects of both mirror therapy and individual GMI components, as well as the most effective implementation strategies and target populations, remain to be determined with greater certainty233. By contrast, pain neuroscience education (PNE) places greater emphasis on helping patients reconceptualize their experience of pain. Evidence suggests that PNE can improve pain, functional outcomes, and select psychological or behavioural measures in individuals with chronic musculoskeletal pain, thereby supporting its role within centrally oriented rehabilitation strategies234. PNE acknowledges the role of peripheral tissue injury in pain generation, but it highlights that persistent pain does not always correspond directly to the degree of ongoing tissue damage. Instead, the development and maintenance of pain are also influenced by central processing, cognitive interpretation, and behavioural responses. Based on these principles, PNE and GMI may be used together in clinical practice. While PNE focuses on modifying the patient’s understanding of pain, GMI aims to promote functional recovery by progressively activating the sensorimotor networks. Virtual reality (VR) training is now being more widely adopted in rehabilitation practice. Compared to traditional approaches, VR offers a more immersive and interactive environment, which can increase patient engagement during therapy. Evidence from current studies suggests that, for upper-limb and balance rehabilitation among burn survivors, VR-based interventions are linked to reductions in pain and anxiety, as well as longer training sessions. These findings indicate that VR could improve adherence and enhance the overall rehabilitation experience. By facilitating multisensory integration and providing real-time feedback, VR may further strengthen the activation of central sensorimotor pathways and support neuromuscular reeducation. Nevertheless, most research on VR in burn rehabilitation has focused primarily on analgesic and psychological outcomes. The specific effects of VR on motor recovery, as well as the mechanisms underlying these effects, remain to be established more clearly230,235. Currently, most of the evidence supporting GMI, PNE, and VR comes from studies involving individuals with complex regional pain syndrome, phantom limb pain, or chronic musculoskeletal pain. In contrast, for burn patients, there is a lack of direct clinical evidence to confirm whether centrally targeted rehabilitation strategies provide similar benefits236. Therefore, these approaches should be considered adjunctive rehabilitation options that are supported by theoretical rationale and translational potential. They should not yet be viewed as standardized pathways within burn rehabilitation until more robust evidence becomes available. Besides, recent advances in genetic neuromodulation have further expanded the frontier of neurorehabilitation. Experimental studies using optogenetic or bioluminescent optogenetic activation of injured peripheral motor pathways have shown that brief, targeted increases in neuronal activity can enhance axonal regeneration, reinnervation, and functional motor recovery in vivo, including in sciatic nerve injury models expressing channelrhodopsin in motoneurons237–239. These approaches increase the number of reinnervated motor endplates and augment electrophysiologic indicators of neuromuscular reconnection, suggesting that activity-dependent stimulation can accelerate peripheral nerve repair. Similarly, chemogenetic activation of motor neurons through excitatory designer receptors has been shown to increase both the number and length of regenerating axons, indicating that sustained neuronal activation reproduces key biological effects of exercise and promotes more effective reinnervation. Collectively, these emerging technologies demonstrate how precision neuromodulation can integrate neural regeneration with functional reeducation and provide a mechanistic basis for advancing burn rehabilitation toward individualized, circuit-level targeting. Scar remodelling and skin regeneration Scar remodelling and skin regeneration constitute essential stages of postburn rehabilitation and largely determine long-term cosmetic outcomes, functional recovery, and overall quality of life. Burn injuries often cause extensive dermal matrix disruption, impaired epidermal renewal, dysregulated crosstalk between regenerating nerves and fibroblasts, and irreversible loss of appendages such as hair follicles and sebaceous glands240. These changes predispose survivors to hypertrophic scar formation, persistent pruritic pain, and contractural deformities, which, in severe cases, limit joint mobility and contribute to psychological distress241. Conventional antiscar treatments, including anti-inflammatory or antifibrotic pharmacotherapy and physical rehabilitation, provide partial benefit but often lack the specificity needed to modulate complex, multilayered tissue repair processes242 (Fig. 5). Mechanisms of scar formation and neuromodulatory interventions. Burn injury disrupts peripheral sensory nerves and triggers the release of substance P and calcitonin gene related peptide. Substance P activates NK1R on mast cells and macrophages, inducing histamine, IL1β and TNFα release, which increases vascular permeability, amplifies inflammation, stimulates fibroblast activity and promotes excessive type I and type III collagen deposition. Calcitonin gene related peptide influences immune cell polarization through RAMP1 and supports fibroblast proliferation and extracellular matrix remodelling, contributing to hypertrophic scar formation. Neuromodulatory treatments modify these neural, inflammatory and fibrotic pathways. TENS and taVNS reduce abnormal neural signalling and limit neuropeptide release. taVNS also activates the cholinergic anti inflammatory reflex and suppresses cytokine production. PEMF reduces TGFβ Smad activity, decreases αSMA expression and limits myofibroblast differentiation. Combined photonic, acoustic and electrical interventions, including PDL, ESWT and TENS, enhance collagen remodelling, improve microcirculation and reduce scar hypertrophy. Recent evidence suggests that neuromodulation may offer additional strategies for controlling scar formation after burn injury. Noninvasive modalities such as PEMFs, TENS, transcutaneous auricular vagus nerve stimulation (taVNS), and combined photonic–acoustic–electrical regimens such as pulsed-dye lasers with microcurrents have been demonstrated to alleviate hypertrophy and pruritus. Reported mechanisms include the modulation of TGF-β and Smad signalling, reduction in α-smooth muscle actin expression, reorganization of the collagen architecture, and enhancement of local microvascular perfusion243. In addition, laser-based interventions, particularly ablative fractional CO2 laser, have emerged as an important adjunct in hypertrophic burn scar management, with reported benefits extending beyond scar appearance to pain and pruritus relief, improvement in scar thickness and texture, and broader functional recovery244. In parallel, preclinical studies using optogenetic and chemogenetic approaches in peripheral nerve injury models have demonstrated that activity-dependent neuromodulation can promote axonal regeneration and functional recovery. In a motor-axon repair model, repeated optogenetic activation of motoneurons enhanced axonal regeneration and improved neuromuscular responses245. In a separate study, chemogenetic activation via designer receptors increased the number and length of regenerating axons in a sciatic nerve injury model246. Together, these findings indicate that precise modulation of neuronal excitability can reproduce biological effects similar to those of exercise and support tissue repair. Although these tools have not yet been translated to cutaneous or skin-appendage regeneration, their regenerative potential provides a conceptual framework for future applications in skin repair and appendage reconstruction. Pulsed electromagnetic field PEMF is a noninvasive physical stimulus that generates electromagnetic pulses of defined frequency and intensity to induce bioelectric and biochemical responses in tissues, thereby modulating cellular behaviour, gene expression, and the tissue microenvironment. By controlling parameters such as frequency (in hertz), waveform, intensity as magnetic flux density (usually in millitesla or microtesla), and pulse width, weak currents are induced in the target tissue that activate membrane ion channels such as calcium, sodium, and potassium channels and trigger downstream signalling cascades247. Accumulating in vitro and preclinical evidence has demonstrated that PEMFs exert regulatory effects on dermal fibroblast activity and extracellular matrix dynamics. PEMF exposure has been shown to alter fibroblast proliferation and migratory capacity, attenuate myofibroblast differentiation, and modulate profibrotic signalling networks, including the TGF-β/Smad axis, along with key inflammatory mediators implicated in wound healing and scar pathobiology248. In a mouse model of myocardial infarction, PEMFs significantly reduced the fibrotic scar burden. The antifibrotic effect was diminished by the administration of a TGF-β agonist, suggesting that PEMFs act partially through the suppression of TGF-β1 and Smad3 activation249. Other forms of biophysical stimulation similarly modulate the fibroblast phenotype. In hypertrophic scar–derived fibroblasts, ultrasound exposure led to reduced expression of α-smooth muscle actin and TGF-β1, accompanied by decreased collagen synthesis and modest antiproliferative effects, indicating that physical stimulation can limit fibroblast activation and excessive matrix deposition250. On the basis of these observations, pulsed electromagnetic field (PEMF) stimulation has been shown across several preclinical models to modulate wound-healing biology at both the cellular and tissue levels. In endothelial cells, PEMF exposure enhances angiogenic behaviour by promoting a metabolic shift toward glycolysis and increasing tube-network formation251. In diabetic full-thickness wound models, PEMF accelerated wound closure, improved granulation tissue vascularization, and upregulated fibroblast growth factor-2 (FGF-2), supporting a pro-regenerative role153. Additional studies in fibroblasts indicate that electromagnetic stimulation can alter proliferation, migration, and myofibroblast differentiation, with evidence suggesting that modulation of the TGF-β/Smad signalling and inflammatory pathways is a potential mechanism for disrupting persistent fibrotic feedback loops252. These findings indicate that PEMFs and related biophysical stimuli modulate stromal-cell activity through defined metabolic and signalling pathways, with consequent effects on angiogenesis, fibroblast activation, and matrix remodelling. TENS and taVNS for the Triad of Scar Pruritus, Pain, and Hypertrophy Hypertrophic scar tissue exhibits persistent neurogenic inflammation, in which dysregulated sensory innervation releases pruritogenic and profibrotic mediators that enhance fibroblast activation and matrix deposition25. The resulting inflammatory activity and mechanical stress sensitize peripheral sensory endings and contribute to the triad of pruritus, pain and hypertrophy frequently observed after burn injury253. Nonspharmacologic neuromodulation approaches, such as TENS and taVNS, have been investigated as potential methods to attenuate abnormal innervation and chronic inflammation in hypertrophic scars. Available reviews of electrical stimulation in cutaneous wounds and systematic analyses of auricular vagus nerve stimulation have reported preliminary evidence of symptom reduction or the modulation of inflammatory activity, although large randomized trials in burn-related hypertrophic scars are unavailable254,255. A clinical cohort involving thirty patients with more than one hundred and forty symptomatic raised dermal scars treated with a biofeedback-guided electrical stimulation protocol demonstrated reductions in subjective symptoms and objective scar scores, with median modified Manchester scale scores decreasing from 14 to 11 over two months and pain and itch scores falling from baselines of 7 and 6 to a median of 0256. A separate prospective case series including eighteen patients with chronic painful and pruritic raised dermal scars reported significant improvements following two months of Fenzian wave stimulation, with reductions in pain from Day 0 to Month 1 (P < 0.05) and early improvement in pruritus from Day 0 to Week 1 (P < 0.05), accompanied by a trend toward increased haemoglobin levels and dermal perfusion on full-field laser perfusion and spectrophotometric intracutaneous analysis257. These findings indicate potential neuromodulatory and microcirculatory effects. Although these observations are promising, the current evidence is limited by small sample sizes and nonrandomized study designs. Further randomized controlled trials are needed to determine the therapeutic value of transcutaneous electrical nerve stimulation and auricular transcutaneous vagus nerve stimulation in the management of postburn hypertrophic scars. Combined photonic, acoustic, and electrical modulation Hypertrophic scar development reflects the convergence of vascular proliferation, inflammatory activation and extracellular-matrix remodelling. These processes evolve dynamically, and their biological heterogeneity limits the effectiveness of physical modalities applied individually. Multimodal energy-based intervention has therefore gained prominence as a strategy to address distinct components of the pathological microenvironment. Pulsed dye lasers (PDLs) at 585–595 nm selectively target haemoglobin within the microvasculature of pathological scars, leading to reduced erythema and capillary dilation and contributing to collagen remodelling and improved scar texture258. Clinical studies of hypertrophic burn scars consistently report decreases in erythema and thickness, relief of pruritus, and improved pliability, suggesting that the PDL is a nonsurgical modality for scar management259. In thyroidectomy scars, a prospective trial using a 595-nm PDL and three-dimensional imaging revealed significant reductions in Vancouver scar scale scores together with decreases in scar height, pigmentation, and vascularity260. A larger retrospective cohort further demonstrated that initiating PDL within three weeks after surgery achieved greater improvements in Vancouver scar scale scores and Antera 3D–derived pigmentation and erythema indices than starting treatment at 4–6 weeks, indicating that early vascular-targeted laser intervention can attenuate progression toward hypertrophic scarring261,262. Acoustic modalities such as low-energy ultrasound and extracorporeal shockwave therapy (ESWT) are increasingly used in scar management. ESWT has been associated with softening and flattening of burn-related hypertrophic scars. Mechanistic studies have reported downregulation of type I and type III collagen and TGF-β expression, together with increased matrix metalloproteinase activity, suggesting attenuation of fibrosis at the molecular level263. Additional work has shown that weekly ESWT over several weeks alters the extracellular matrix composition, reduces scar thickness and improves elasticity, whereas low-intensity pulsed ultrasound enhances nitric oxide and growth factor release by scar fibroblasts, changes that support microvascular perfusion and remodelling264. Building on these modality-specific benefits, combined energy-based approaches are being investigated as a means of achieving broader remodelling. A multimodal protocol incorporating radiofrequency fields, electrical pulses and negative-pressure massage applied for three months to twenty-six mature scars resulted in smoother surfaces, reduced thickness and improved hydration and elasticity. The colour more closely resembled that of adjacent skin, and histological examination revealed collagen reorientation and new elastin formation, suggesting a wider remodelling effect than typically observed with single-modality therapy265. CO₂ fractional ablative laser and low-level laser therapy In recent years, laser-based interventions have become an integral part of hypertrophic burn scar management. In addition to improving scar appearance and texture, their impact on pain, pruritus, and functional symptoms has attracted increasing attention. Advances in laser technology have led to a growing body of evidence demonstrating that laser treatment can reduce scar thickness, neuropathic pain, and pruritus. Improvements in pigmentation, erythema, pliability, texture, and scar height have also been reported. These benefits are thought to reflect broader clinical improvements achieved through scar remodeling. The effects of laser therapy are therefore regarded as extending beyond cosmetic enhancement266. Among current laser modalities, ablative fractional CO2 laser (AFCO2 L) has provided the most consistent evidence for clinical benefit in hypertrophic burn scars. These benefits extend beyond changes in scar structure. A prospective before-and-after cohort study demonstrated significant improvement in both objective scar features and patient-reported symptoms following laser therapy. Physician-assessed Vancouver Scar Scale scores and patient-reported UNC Scar Scale scores both declined significantly after treatment, indicating that laser intervention can enhance scar thickness, colour, and pliability while also alleviating symptoms such as pain and pruritus. This finding was supported by a subsequent large prospective cohort study with extended follow-up267. In a cohort of 147 burn patients who received a total of 415 laser treatments, physician-rated Vancouver Scar Scale scores decreased from 10.43 to 5.16 and then to 3.29 at 25 months. Patient-reported UNC4P scores also decreased from 5.40 to 2.05 and then to 1.74. These results suggest that laser therapy may provide not only relatively rapid improvement but also sustained benefits with repeated treatments and long-term follow-up in patients with hypertrophic burn scars268. More evidence further strengthens these observations. In a prospective randomized controlled trial involving 20 burn patients, three sessions of AFCO₂L resulted in significant reductions in scar pain (p = 0.047) and pruritus (p < 0.01) at 6 weeks compared with control-treated areas (Douglas et al.)269. Similarly, the ELIPSE randomized controlled trial (n = 15) demonstrated significant improvements in patient-reported scar thickness (p = 0.01 at 3 months; p = 0.04 at 6 months) and scar irregularity (p = 0.02 at 3 months), accompanied by improvements across all domains of the Brisbane Burn Scar Impact Profile, indicating broader functional benefits244,269. Beyond improvements in scar characteristics, AFCO2 L treatment has also been linked to reductions in pain, pruritus, and sleep-related symptoms. A prospective cohort study found that CO2-AFL therapy significantly enhanced sleep quality in patients with hypertrophic scars, with concurrent decreases in pain and pruritus scores. Improvements in sleep disturbance were associated with better quality of deep sleep. These findings indicate that the clinical value of laser therapy includes not only visible scar remodeling but also relief of symptoms and improvements in daily functioning270. In contrast, low-level laser therapy (LLLT) is more frequently used as a conservative adjunctive intervention in burn scar management. Evidence suggests that low-level laser treatment at 400 mW and 670 nm can lead to some improvement in the macroscopic appearance of burn scars and may also relieve pruritus and pain. Despite these possible benefits, the overall efficacy of LLLT appears modest, and treatment responses vary considerably among individuals. Currently, LLLT is best considered an adjunctive strategy for symptom management rather than a primary approach to scar remodeling271. Broader clinical evidence from laser-based interventions further contextualizes these findings and provides a more comprehensive perspective on their therapeutic role.A retrospective cohort study involving 837 burn patients undergoing 4005 laser sessions demonstrated consistent improvements in scar-related symptoms such as pruritus and stiffness. Notably, this study also highlighted a shift in clinical practice toward earlier intervention, with the mean scar age at treatment decreasing from over 5000 days to 111 days, alongside a transition toward outpatient-based care, with 66% of procedures performed in outpatient settings272.These findings collectively suggest a shift toward earlier, more accessible, and longitudinally integrated laser-based burn scar management. Neuromodulation and skin regeneration Neuromodulation contributes to scar remodelling by regulating reciprocal signalling between cutaneous nerves and the regenerating dermal matrix. During physiological repair, peripheral sensory fibres release trophic and regulatory mediators that support keratinocyte stratification, guide epithelial organization and maintain the extracellular environment required for orderly matrix deposition. Experimental disruption of cutaneous innervation results in delayed re-epithelialization and impaired angiogenesis, reflecting the loss of neurotrophic and cytokine inputs essential for fibroblast function and vascular maturation273. These findings indicate that neural signalling is an integral determinant of tissue-repair quality and the subsequent architecture of the developing scar. Deep burn scars commonly lack appendages such as hair follicles and sebaceous glands, which restricts structural restoration. Recent evidence suggests that targeted neuromodulation may influence appendage regeneration. In a murine model, selective activation of TRPV1-positive sensory neurons enhanced postinjury hair regrowth, which was associated with reduced macrophage apoptosis and increased release of reparative mediators that induced dermal fibroblasts to express osteopontin (Spp1). This signalling milieu facilitates the activation of quiescent follicular stem cells and their transition into anagen, indicating a role for sensory-neuron–derived cues in follicular reactivation274. Clinical and experimental evidence shows that hypertrophic scars respond differently to neuromodulatory and energy-based treatments depending on the stage of maturation. Photonic and other energy-based interventions applied during the immature phase of scarring achieve greater control of vascularity, collagen organization and early hypertrophy, with substantially stronger responses observed in scars still undergoing active remodelling275,276. Compared with interventions delivered after full maturation, treatments initiated within the first six to twelve months after injury, a period characterized by increased collagen turnover and cellular plasticity, consistently lead to greater improvements in height, vascularity and surface texture262. Evidence from percutaneous electrical stimulation and extracorporeal shock wave therapy further indicates that early- to mid-stage application more effectively influences inflammatory activity, fibroblast behaviour and extracellular matrix deposition277. In contrast, long-standing scars tend to show clearer improvements in pliability and symptoms such as pruritus and pain, which is consistent with the clinical experience of chronic symptomatic hypertrophic scars treated with electrical stimulation278 and studies reporting enhanced elasticity following shock wave therapy in mature burn scars279. Current clinical management strategies for hypertrophic scars therefore highlight the importance of initiating neuromodulatory or energy-based approaches as early as possible to optimize long-term functional and aesthetic outcomes, a principle consistently emphasized across recent scar management algorithms266. Future perspectives and outlook Despite considerable progress in the management of acute burns, long-term sequelae such as chronic pain, neuromuscular dysfunction, and hypertrophic scarring remain significant barriers to optimal functional recovery and quality of life. While established pharmacological and rehabilitation strategies confer substantial benefits, their efficacy may be limited by enduring neuroplastic changes, persistent inflammation, and aberrant tissue remodelling. The interplay of these mechanisms highlights the necessity for therapeutic approaches that are responsive to the dynamic biological and clinical challenges encountered during burn rehabilitation. Neuromodulation has emerged as a potentially valuable modality for addressing these persistent challenges. Available data indicate that electrical, magnetic, and vagal stimulation techniques can attenuate nociceptive signaling, facilitate neuromuscular retraining, and augment functional recovery. Furthermore, innovative gene-targeted and biophysical neuromodulation strategies have shown promise in modulating neural function, fostering axonal regeneration, and influencing scar formation in preclinical models. Nevertheless, robust clinical data in burn cohorts are scarce, with much of the current evidence drawn from small-scale studies or extrapolated from broader pain and neurorehabilitation literature. Accordingly, future investigations should prioritize the generation of high-quality clinical evidence and the resolution of key translational barriers. Critical areas for exploration include the determination of optimal stimulation parameters, timing of intervention, and criteria for patient selection throughout the continuum of burn recovery. Enhanced phenotyping of pain, functional deficits, and scar evolution, supported by objective assessments such as neurophysiological measurements and advanced imaging, may facilitate the development of more targeted and individualized therapeutic strategies. Moreover, combining neuromodulation with conventional modalities, such as pharmacological analgesia, structured rehabilitation, and scar management, may yield synergistic effects by concurrently targeting diverse aspects of postburn pathology. Technological advancements, such as wearable and noninvasive systems capable of delivering real-time adaptive stimulation, hold promise for expanding treatment accessibility and standardization; however, these innovations warrant rigorous validation within clinically relevant cohorts. In summary, neuromodulation constitutes a targeted and adaptable adjunct to established burn care paradigms. The development of standardized protocols and pragmatic implementation frameworks will be pivotal for facilitating broader clinical integration. Overcoming these challenges may enable the translation of emerging evidence into more effective strategies aimed at optimizing long-term outcomes and quality of life for individuals recovering from burn injury. Supplementary information Transparent Peer Review file Acknowledgements This work was supported by the National Natural Science Foundation of China (82572913 to J.Z.; 82172207 and 81971833 to B.S.), the Scientific Research Project of Hebei Administration of Traditional Chinese Medicine (T2026113 to Z.Q.), and the Natural Science Foundation of Guangdong Province (2020A15151100694 to F.Z.). Author contributions J.Z., S.L., T.L., F.Z. and X.H. conducted the literature review; T.L., Q.Z. prepared the figures and visualization; T.L., Q.Z., F.Z. and X.H. wrote the original draft; J.Z., S.L., B.S. and J.X. reviewed and edited the manuscript; J.Z., B.S. and F.Z. acquired the funding and supported the research; J.Z., B.S. and J.X. conceptualized the stud; J.Z. and S.L. supervised the project. All authors have read and agreed to the published version of the manuscript. Peer review Peer review information Communications Medicine thanks Alessandro Dario and Dale W. Edgar for their contribution to the peer review of this work. A peer review file is available. Data availability No new data were generated or analyzed in this study. Data sharing is not applicable to this article. Competing interest The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Tianjiao Li, Qian Zhang. Contributor Information Shiyu Li, Email: lishiyi@jnu.edu.cn. Junyou Zhu, Email: zhujy73@mail.sysu.edu.cn. Supplementary information The online version contains supplementary material available at 10.1038/s43856-026-01696-2. References Associated Data Supplementary Materials Transparent Peer Review file Data Availability Statement No new data were generated or analyzed in this study. Data sharing is not applicable to this article.